About botulinum toxin

• Education
• Publications from the journal "Plastic Surgery and Cosmetology"
• News from the magazine "Injection Methods in Cosmetology"

Manufacturer

Manufacturer

A drug

Application

Instruction

Registration certificate II N011520/01 dated 15.08.2011

Manufacturer Ipsen

Ipsen is a European pharmaceutical company representing more than 20 drugs on the market in more than 100 countries around the world.
Today, around 4,000 Ipsen employees work under the motto “Innovation for Health”.
The introduction of innovations in medicine that increase the effectiveness of treatment and the level of quality of life of patients is main goal companies.

A defining element of Ipsen's development strategy is the promotion of high-tech drugs in key areas of medicine for the company (oncology, endocrinology, neuromuscular disorders). General medicine medicines, which are widely represented in the company's portfolio, make a significant contribution to the funding of research activities.
Another element of Ipsen's development strategy is the establishment of partnerships with leading pharmaceutical companies in the US, Europe and Japan.

About 700 employees of the company work in four research centers located in Paris, Boston, Barcelona and London. The geographical location of these centers provides Ipsen with undeniable competitive advantages in attracting highly qualified research teams from the world's largest universities to cooperate.

Ipsen has been operating in Russia since 1993. Today, the company's representatives work in more than 35 cities of the country, the staff of the Russian representative office exceeds 150 people.
Ipsen's portfolio in Russia includes drugs used in general therapeutic practice, as well as innovative drugs.

One of the leading drugs in the Ipsen portfolio is the drug Dysport®- complex botulinum toxin type A - hemagglutinin 500 IU in a vial. Peripheral muscle relaxant of prolonged action.

Since 1999, Dysport® has been registered in Russian Federation according to neurological indications. The drug is widely used in Russia and has established itself among doctors and patients as a highly effective and safe treatment for local muscle spasm.

Ipsen Pharma is a European pharmaceutical company with about 4,000 employees, marketing more than 20 drugs, present in more than 100 countries around the world.

Target: Innovation for Health

We strive to significantly improve patient care and quality of life by introducing innovations in medicine that effectively meet therapeutic challenges and meet the needs of patients.

Tasks:

• To be an international pharmaceutical association that brings innovation to patient care.
• Achieve an international presence and become a leader in specialized fields of medicine as well as in the field of general medicine.
• Innovate therapies through partnerships and research, as well as developing our own high-tech developments.
• To attract, develop and support gifted and exceptional people working in a team with professionals of the highest level.
• Create a competitive work environment, providing opportunities for career advancement.

Strategy:

Ipsen's development strategy is based primarily on the complementarity of drugs in the rapidly growing market of biotech drugs (oncology, endocrinology, neuromuscular disorders) and drugs used in general practice(gastroenterology, cognitive impairment, cardiovascular disease), allowing the implementation of funding research activities. Ipsen's strategy is also based on active collaboration with other companies, internationally recognized leaders in the US, Europe and Japan. The geographical location of four research centers - in Paris, Boston, London - gives Ipsen competitive advantage access to leading research universities and institutes, as well as highly professional staff.

Approximately 700 R&D employees work daily to discover and develop innovative medicines to take care of patients' health.

In December 2005, Ipsen's IPO took place on the EuronextTM European Stock Exchange (share code: IPN, ISIN code: FR0010259150).
Official website on the Internet: www.ipsen.com

History: key facts in the development of the Ipsen company

The history of the company dates back to 1929, when Dr. Henri Beaufour founded Laboratoires Beaufour in Dreux, France, specializing in the production of Romarène®, a natural medicine made from rosemary, which is used in the treatment of digestive disorders. In 1954, the company launched Citrate de Betaïne®, a drug used in the symptomatic treatment of dyspepsia. In 1969, the Institut Henri Beaufour, a research center in France, was opened. The period of the 70s is significant for the expansion of Ipsen's activities in the production of drugs of natural origin, which are still one of the main products: Ginkor®, Tanakan®, Smecta®.

During the 1970s, Ipsen concentrated his activities on peptide-engineered drugs, which represented a clear strategic advantage. To successfully implement these activities, the company establishes close relationships with US universities and establishes Research Center for peptides near Boston Universities.

During the 1980s, a collaboration with Debiopharm was established. As a result of this collaboration, the market was launched in 1986 Diferelin® which led the company to international market. In the mid-80s, La Fondation Ipsen was founded, a structure aimed at scientific exchange among the world's leading scientists. The company is confident that this organization has greatly helped and will continue to strengthen relationships with outstanding scientists.

La Fondation Ipsen, in collaboration with international scientific and research institutes holds international meetings that bring together leading experts from:

1. World Health Organization (WHO) - Since 1989, several scientific symposiums have been held on genetics.
2. National Gerontological Organization - various conferences on dementia and cognitive aging.

In the late 80s and early 90s, the company continued international development through the opening of subsidiaries and offices outside France, as well as the acquisition of other companies. Outside of Europe, Ipsen opens a representative office in Southeast Asia - a regional office in Kuala Lumpur (Malaysia) in 1987.

To strengthen its presence in England, Northern Europe and the US, and to expand its biologics portfolio, Ipsen acquires the English company Speywood (then known as Porton International) in 1994, which manufactures Dysport®. In March 1995, Ipsen marketed Somatulin® in France and Forlax® in February 1996.

In 1992, the company entered the Chinese market, where a subsidiary was established in 1997, and in 2000 the production of Smecta® for the Chinese market was opened.

In December 2001 and January 2002, the company launched Somatulin ® Autogel® in England and in France. Subsequently, this product also entered the markets of other countries.

In 2004, the company launched on the market 12 European countries Nutropin®.

In March 2005 in Boston, Ipsen opened science Center for research in the field of biological processes (BioProcess Sciences Research Center), which complemented the existing research center.

The company has entered into a number of partnership agreements to develop research and development activities and expand the product line. Partner companies include: Asterion, Auxilium, Bayer, CEA, Debiopharm, Galderma, Genentech, GTx, Inc., Health Protection Agency (HPA), Indena, Inserm, Massachusetts General Hospital, Medicis, Merck Sharp & Dohme, Novartis, Octagen and Emory University, Radius, Roche, Schwabe, Spirogen, Teijin, Tercica , Tulane University .

Ipsen has been working in Russia since 1993. At the moment, the company is represented in more than 35 cities of the Russian Federation, with a staff of over 150 people. To date, Ipsen's portfolio in Russia includes drugs used in general therapeutic practice, as well as innovative drugs.

Leading positions in the respective segments are:

Segment	Scope of application	Preparations	International name
Market of biotech drugs	Oncology (oncourology) Gynecology Pediatric endocrinology	Diferelin® (Diphereline®) (treatment of hormone-sensitive prostate cancer in men, genital and extragenital endometriosis in women, preparation for surgery for uterine fibroids, use in the in vitro fertilization program for female infertility, treatment of central forms of premature sexual development in children ).	Triptorelin(analogue of gonadotropin - releasing hormone)
	Endocrinology Oncology	Somatulin® (Somatuline®) (treatment of acromegaly, symptomatic therapy of neuroendocrine tumors)	Lanreotide (similar to somatostatin)
	Neurology aesthetic medicine	Dysport® (Dysport®) (Treatment of blepharospasm, hemifacial spasm, spastic torticollis, hand spasticity after a stroke, hyperkinetic (mimic) facial folds (wrinkles) in adults, axillary hyperhidrosis. Treatment of dynamic foot deformity caused by spasticity in children with cerebral palsy from 2 years of age.).	Botulinum A toxin(muscle relaxant. Acetylcholine release inhibitor)
The Market for General Therapeutic Medicines	Gastroenterology	Smecta® (Smecta®) (treatment of acute and chronic diarrhea in children and adults) Forlax® (Forlax®) (treatment of constipation in children and adults) Fortrans® (Fortrans®) (cleansing the intestines before research and surgical interventions)	Diosmectite(adsorbent-cytomucoprotector) Macrogol 4000(osmotic laxative) > Ipsen Pharma / Ipsen Pharma, LLC (Moscow) This information cannot be used for self-treatment! Be sure to consult with a specialist! International Corporation Ipsen Pharma / Ipsen Pharma is a group pharmaceutical companies, operating all over the world, and having its offices in 49 countries, including Russia. The company has focused its efforts on the development and production of original narrow-profile drugs. Oncology, neurology, endocrinology, general therapy, aesthetic medicine are identified as priority areas. Ipsen Pharma has its own research and development department, which includes two research centers. One of them, which explores the course of biological processes, was built in Boston in 2005. The Russian representative office of the company was opened in 1993 in Moscow. Now its regional divisions are located in 35 cities of Russia, and the staff exceeds 150 people. There are 16 drugs from all the above groups on the country's market. Ipsen Pharma produces: venotonic agent and angioprotector Ginkor Fort® in capsules with active ingredients ginkgo biloba extract, heptaminol and troxerutin for the treatment of peripheral vein pathology and uncomplicated hemorrhoids; external agent Ginkor Gel in the form of a gel for local percutaneous action on superficial veins with anti-edematous and protective action; anticancer agent Diferelin®- a synthetic analogue of the gonadotropic releasing factor in the form of a lyophilizate for the preparation of a long-acting suspension. Diferelin inhibits the production of gonadotropin, causing inhibition of the function of the genital gonads in both sexes. Used for endometriosis, uterine fibromyoma, prostate cancer; peripheral muscle relaxant Dysport® in the form of a lyophilisate containing a complex of botulinum toxin A and hemagglutinin, used to treat blepharospasm, spastic contraction of mimic muscles and pronounced mimic wrinkles; combined antimicrobial agent Intetrix® in capsules for the treatment of acute diarrhea in intestinal infections caused by pathogenic bacteria, fungi, protozoa; drops Colme® for the treatment of alcohol dependence. Simultaneous administration of the drug and alcohol causes unpleasant sensations that form disgust; Nutropin AQ® containing recombinant growth hormone somatotropin, identical to the pituitary. It is used in children and adults with growth retardation associated with hormone deficiency; Paxeladin®- an antitussive agent with a central mechanism of action for the treatment of dry unproductive cough in various pathologies; enzyme preparation Pancitrate® in capsules with pancreatin, amylase, lipase, proteases for the replacement treatment of functional pancreatic insufficiency, improving the digestion of food when overeating, preparing for research; antidiarrheal drug Smecta® with an adsorbing mechanism of action in the form of a powder used for the preparation of an oral suspension; Somatulin®- a synthetic analogue of the hormone somatostatin in the form of a lyophilisate for injection. Somatulin suppresses the secretion of growth hormone somatotropin in case of its excessive production in acromegaly, carcinoid tumors; synthetic analogue of somatostatin Somatulin Autogel® in the form of a gel for subcutaneous administration, used for the treatment of acromegaly and long-term treatment of patients with high levels of growth hormone; herbal psychoanaleptic Tanakan® based on ginkgo biloba extract in tablets and ampoule solution for the treatment of disorders of brain, visual, auditory functions of vascular origin; laxative Forlax® in powders for oral administration with an osmotic mechanism of action for the treatment of chronic constipation of various etiologies; laxative drug Fortrans® based on macrogol with osmotic properties for bowel preparation before diagnostic procedures and surgical interventions; hypnotic drug Circadin® in tablets to improve the quality of sleep and its duration in elderly patients suffering from insomnia. Related Articles Hassp for catering Storage and use of fertilizers Do I need to close the greenhouse with tomatoes at night? Methods for protecting cherries from birds How to scare away birds from cherries creative atmosphere autumn creative family festival Latest Articles 2022-03-26 18:06:30 Cylinders for compressed gases 2022-03-20 06:19:03 Enterprise production plan: what is it? 2022-03-14 22:16:45 Tattoo parlor license Popular Articles For beginners: breeding a broiler at home Boiled water for broilers Only lovers will survive Features of advertising aimed at children retouching old photos in photoshop retouching old photos What is an NPO: decoding, definition of goals, types of activities Does a non-profit organization have the right Editor's Choice 2022-01-28 10:45:17 Gleb Nikitin First Deputy In 1999, Nikitin received a diploma from the St. Petersburg State University of Economics and Finance. In 2004, Gleb Sergeevich graduated from St. Petersburg State University, ... 2022-01-23 12:56:25 drawings of a brigantine (no title) Basic data of the yacht Overall length (with bowsprit), m 10.00 Overall hull length, m 8.65 DWL length, m 7.00 Overall width (with... 2022-01-18 11:39:17 Activity Licensing In Russia, certain types of business activities require a permit or license to be obtained. All in the list... 2022-01-13 15:41:32 Own home business Contextual advertising for a webmaster Today I want to talk about ways to monetize the site, i.e. consider not all possible options for making money on the Internet (I already wrote about them), namely ... 2022-01-03 14:59:18 Diarrhea in broilers: causes and what to do? Growing healthy, productive offspring of broiler chickens is within the power of every farmer. But for this it is not enough to own a large livestock, you need to be able to ... rin-tek.ru Asset Analysis Analytics Odds Methodology turnover Cost price Theory Factor analysis The financial analysis